BIO 2026 brought together leaders from across the biotechnology and pharmaceutical ecosystem, with discussions spanning drug discovery, AI, advanced therapies, biomanufacturing, clinical development, biodefense, regulation, and dealmaking.
Under the theme “Driven by Purpose,” the four-day event featured 130+ sessions across 18 focus areas, highlighting how emerging technologies and changing market conditions are reshaping the life sciences industry.
This report analyzes companies exhibiting at BIO 2026 across drug development, CDMO services, advanced therapies, biomanufacturing, AI-enabled drug discovery, analytical services, and pharmaceutical infrastructure. It examines their technology frameworks, industrial problems, solutions, commercialization maturity, funding, and intellectual property activity.
BIO International Convention 2026 highlighted a biotechnology landscape increasingly focused on scaling innovation from scientific discovery to commercial and clinical application. AI is moving beyond pilots into drug discovery, clinical trial recruitment, and R&D operations, while advanced modalities such as cell and gene therapies, ADCs, xenotransplantation, and longevity science continue to progress toward real-world pipelines.
At the same time, biomanufacturing and supply-chain resilience are becoming strategic priorities. Companies are expanding capabilities in large-scale biologics production, AAV and ADC manufacturing, LNPs, sterile fill-finish, modular facilities, and domestic production to address growing complexity and geopolitical uncertainty.
The broader takeaway is clear: biotech innovation is increasingly being judged not only by the strength of the science, but by how effectively it can be scaled, manufactured, protected, and brought to market.
Drug discovery requires extensive experimentation
AI-powered discovery and virtual experimentation
Turbine, CB Therapeutics
Biologics require increasingly large manufacturing capacity
Ultra-large-scale bioreactors and integrated CDMO platforms
BiBo Biopharma
Advanced therapies need specialized manufacturing
Dedicated AAV, ADC, LNP and nanomedicine platforms
Andelyn, Abzena, Ardena
Global supply chains remain vulnerable to disruption
Domestic and geographically diversified manufacturing
HANS Scientific, AbbVie Contract Manufacturing
Manufacturing facilities take significant time to build
Modular GMP facility design and construction
Pharmadule Morimatsu
Natural extraction limits access to rare compounds
AI-guided fermentation and biosynthesis
CB Therapeutics
The Bigger Signal
The strongest signal from BIO 2026 is that biotech innovation is increasingly being defined by the infrastructure behind the science.
AI may accelerate discovery, but companies still need the data, manufacturing capacity, regulatory infrastructure, specialized equipment, and supply-chain resilience required to turn those discoveries into products. BIO 2026 therefore points toward a more integrated biotech ecosystem where AI, biology, manufacturing, data, and infrastructure are converging.
Three shifts stand out:
1. From AI pilots to AI-enabled workflows
The conversation is moving from “Can AI help?” to “Where does AI deliver measurable R&D value?” BIO’s programming specifically examined AI adoption, ROI, agentic AI, data quality, cybersecurity, and AI’s role across discovery and development.
2. From scientific breakthroughs to manufacturing readiness
Advanced modalities are creating new manufacturing requirements. Companies such as Andelyn, Ardena, Abzena, and BiBo are addressing increasingly specialized needs across AAVs, ADCs, LNPs, HPAPIs, and large-scale biologics production.
3. From global efficiency to supply-chain resilience
Geopolitical uncertainty is making where and how products are manufactured a strategic consideration. Domestic capacity, multi-site networks, modular facilities, and localized infrastructure are becoming important differentiators. The report’s HANS Scientific analysis, for example, highlights domestic sterile manufacturing and WFI production as responses to geopolitical and logistics risks.
What R&D and Innovation Teams Should Watch Next
Where Biotech Innovation Is Focusing:
GlobalData combines drug-pipeline intelligence, clinical trials, regulatory milestones, patent information, pricing, and market forecasts across 290+ proprietary datasets, creating an integrated intelligence layer for BD and strategy teams.
The Biotech Bottleneck
ADC programs often rely on separate development and manufacturing vendors, creating handoff gaps and delays.
The Solution
Abzena combines antibody discovery, cell line development, bioconjugation and GMP manufacturing.
Core Innovation Mechanism
ThioBridge enables site-specific conjugation. AbZelectPRO™ supports cell line development, while EpiScreen 2.0 screens for immunogenicity.
Founded
2013
Headquarter
USA
Funding
~ $65M
TRL
Clinical and commercial GMP manufacturing
IP
Yes
Website
The Biotech Bottleneck
Gene therapy developers face complex AAV process development and difficult transfers into GMP production.
The Solution
Andelyn provides AAV development and manufacturing, supported by 500+ cGMP batches and 85+ global clinical trials.
Core Innovation Mechanism
AAV Curator® applies data-driven process optimization. DIGITAL CDMO® supports structured technology transfer and real-time data sharing.
Founded
2020
Headquarter
USA
Funding
~ $200M
TRL
Clinical and commercial AAV manufacturing
IP
No
Website
The Biotech Bottleneck
Natural extraction can limit the availability and consistency of rare bioactive compounds.
The Solution
CB Therapeutics uses AI-guided yeast fermentation to produce cannabinoids and other bioactive molecules.
Core Innovation Mechanism
Engineered enzymes and microorganisms create biosynthetic production routes. Patent examples cover cannabinoid and alkaloid pathways.
Founded
2015
Headquarter
USA
Funding
~ $11.62M
TRL
Pilot-to-commercial fermentation; broader scale-up underway
IP
Yes
Website
The Biotech Bottleneck
Late-stage biologics programs need reliable production capacity and a clear route to commercial scale.
The Solution
BiBo combines cell line development, GMP manufacturing and facility engineering across the CMC lifecycle.
Core Innovation Mechanism
Its PanFlex® Engineering platform supports large-scale mammalian cell culture and customized manufacturing infrastructure.
Founded
2014
Headquarter
China
Funding
–
IP
No
Website
The Biotech Bottleneck
Facility construction can delay manufacturing readiness and require substantial upfront investment.
The Solution
Pharmadule Morimatsu delivers modular pharmaceutical facilities designed for phased expansion.
Core Innovation Mechanism
Prefabricated, factory-tested modules shift construction work off-site and allow capacity to expand with program needs.
Founded
2011
Headquarter
Sweden
Funding
$50M – $100M
IP
No
Website
We provide end-to-end intelligence and scouting services to help you navigate the complex innovation landscape and stay ahead of the competition.
Ready to explore a custom project?
Our analysts are ready to help you build your innovation roadmap.
